View on Pubmed.gov 31601400 | View on doi.org 10.1016/bs.pmbt...
Calpain in the cleavage of alpha-synuclein and the pathogenesis of Parkinson's disease.
- Department of Microbiology and Immunology, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, United States.
- Department of Microbiology and Immunology, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, United States; Department of Neurosurgery, Medical University of South Carolina, Charleston, SC, United States; Ralph H. Johnson Veterans Administration Medical Center, Charleston, SC, United States.
- Department of Microbiology and Immunology, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, United States. Electronic address: haque@musc.edu.
Abstract
Parkinson's disease (PD) devastates 6.3 million people, ranking it as one of the most prevalent neurodegenerative motor disorders worldwide. PD patients may manifest symptoms of postural instability, bradykinesia, and resting tremors as a result of increasing α-synuclein aggregation and neuron death with disease progression. Therapy options are limited, and those available to patients may worsen their condition. Thus, investigations to understand disease progression may help develop therapeutic strategies for improvement of quality of life for patients suffering from PD. This review provides an overview of α-synuclein, a presynaptic neuronal protein whose function in the healthy brain and PD pathology remains a mystery. This review also focuses on calcium-induced activation of calpain, a neutral protease, and the subsequent cascade of cellular processing of α-synuclein and emerging defense responses observed in experimental models of PD: microglial activation, dysregulation of T cells, and inflammatory responses in the brain. In addition, this review discusses the events of cross presentation of synuclein peptides by professional antigen presenting cells and microglia, induction of inflammatory responses in the periphery and brain, and emerging calpain-targeted therapeutic strategies to attenuate neuronal death in PD.
References
Dev Comp Immunol. 2002 Nov;26(9):775-84
PLoS One. 2016 Jun 09;11(6):e0157175
Biochemistry. 2007 Jun 19;46(24):7107-18
Front Immunol. 2012 Feb 29;3:24
Cited by 19 citations (total)
Journal Article
Potent inhibitors of toxic alpha-synuclein identified via cellular time-resolved FRET biosensors.
Electronic publication date June 30, 2021
Anthony R Braun [...] Jonathan N Sachs et al.
We have developed a high-throughput drug discovery platform, measuring fluorescence resonance energy transfer (FRET) with fluorescent alpha-synuclein (αSN) biosensors, to...
Journal Article Review
Insights into Calpain Activation and Rho-ROCK Signaling in Parkinson's Disease and Aging.
Electronic publication date May 25, 2024
Amy Gathings [...] Azizul Haque et al.
Parkinson's disease (PD), a progressive neurodegenerative disease, has no cure, and current therapies are not effective at halting disease progression....
Conflict of interest statement
MeSH
- •
- •
- •
- •
- •
- •
- •
- •
- •
- •
- •
Specialties
- •
- •
- •
- •
- •
- •
- •
- •
Substances
- •
Copyright
© 2019 Elsevier Inc. All rights reserved.